Segmental vitiligo - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Segmental Vitiligo – Comprehensive Medical Guide

Segmental Vitiligo – Comprehensive Medical Guide

Overview

Segmental vitiligo (SV) is a distinct form of vitiligo characterized by a unilateral (one‑sided) loss of skin pigment that follows a dermatomal or segmental pattern. Unlike the more common non‑segmental vitiligo (NSV), which often appears symmetrically on both sides of the body, SV usually appears on a single, well‑defined area and stabilizes within 1–2 years after onset.

  • Typical age of onset: 5–30 years, though it can occur at any age.
  • Gender distribution: Slight male predominance in some series, but overall gender ratio is roughly equal.
  • Prevalence: SV accounts for 5–10 % of all vitiligo cases worldwide. With an estimated global vitiligo prevalence of 0.5–2 % (≈ 40‑80 million people), SV affects roughly 2‑8 million individuals.[1][2]

SV often begins as a single, well‑circumscribed white patch that may expand rapidly over weeks to months before stabilizing. Because it follows a dermatome, the affected area may involve the face, neck, trunk, or extremities, but never crosses the midline.

Symptoms

The hallmark of segmental vitiligo is depigmentation, but patients may experience a range of associated signs.

  • White or hypopigmented macules – sharply demarcated, usually 2 cm–10 cm in diameter at onset.
  • Rapid early spread – lesions can enlarge quickly for 6–12 months before plateauing.
  • Asymmetrical distribution – confined to one side of the body; never crosses the midline.
  • Segmental pattern – follows a dermatome (e.g., C3‑C4, T4‑T5) or a linear “band‑like” distribution.
  • Trichrome or leucotrichia – loss of pigment in the hair within the affected area, producing white or gray hairs.
  • Koebner phenomenon (less common) – new depigmented patches may develop at sites of trauma, friction, or pressure.
  • Absence of itching or pain – lesions are usually asymptomatic, though some patients report mild burning or sensitivity to sunlight.
  • Psychological impact – body‑image concerns, anxiety, or depression may arise, especially when lesions affect visible areas like the face.

Causes and Risk Factors

The exact cause of segmental vitiligo remains uncertain, but several mechanisms have been proposed.

Autoimmune theory

Like NSV, SV may involve an immune‑mediated attack on melanocytes. However, the rapid, unilateral course suggests a localized trigger rather than a systemic autoimmune response.

Neural hypothesis

Because SV follows dermatomal patterns, many researchers propose a neuro‑cutaneous link. Abnormal release of neuropeptides (e.g., substance P) or oxidative stress from sympathetic nerves could damage melanocytes in a specific segment.[3]

Genetic factors

Family history is less common in SV than NSV, indicating a weaker genetic component. Still, certain HLA types (e.g., HLA‑DR4) have been reported more frequently in vitiligo patients overall.

Environmental triggers

  • Physical trauma (cuts, burns, acupuncture) that initiates a Koebner response.
  • Sunburn or chronic UV exposure that may precipitate oxidative stress.
  • Certain chemicals (phenols, catechols) that are toxic to melanocytes.

Risk factors

  • Age < 30 years (peak incidence).
  • Personal or family history of autoimmune diseases (e.g., thyroiditis, type 1 diabetes), though less strongly linked than in NSV.
  • History of skin trauma in the affected segment.

Diagnosis

Diagnosis of segmental vitiligo is primarily clinical, based on history and visual examination. The goal is to differentiate SV from other hypopigmentary disorders such as pityriasis alba, tinea versicolor, or post‑inflammatory hypopigmentation.

Clinical evaluation

  1. History taking – onset age, rate of spread, prior trauma, family autoimmune disease.
  2. Physical examination – inspect distribution, note unilateral pattern, assess for leukotrichia.
  3. Wood’s lamp examination – ultraviolet light enhances contrast, confirming loss of melanin.

Ancillary tests (when needed)

  • Biopsy – rarely required; histology shows absence of melanocytes in the basal layer.
  • Autoantibody panels – thyroid function tests (TSH, free T4) and antithyroid antibodies to screen for associated autoimmune disease.
  • Dermatoscopy – helps differentiate SV from other hypopigmented lesions by visualizing vascular and pigment patterns.

Diagnostic criteria (adapted from the Vitiligo Global Issues Consensus)

  • Unilateral, well‑circumscribed depigmented macules.
  • Distribution respecting a dermatome or linear segment.
  • Rapid progression for ≤ 12 months followed by stability.
  • Absence of symmetrical lesions elsewhere (or minimal NSV lesions).

Treatment Options

Because SV stabilizes early, therapeutic goals focus on repigmentation, cosmetic improvement, and psychosocial support. Treatment choices depend on lesion location, size, duration, and patient preference.

Topical therapies

  • High‑potency corticosteroids (e.g., clobetasol propionate 0.05 %): applied twice daily for up to 12 weeks. Benefits: may trigger melanocyte migration. Risks: skin atrophy, telangiectasia.
  • Calcineurin inhibitors (tacrolimus 0.1 % ointment, pimecrolimus 1 % cream): useful for facial lesions, especially in children, with minimal irritation.
  • Topical JAK inhibitors (ruxolitinib 1.5 % cream): FDA‑approved for vitiligo; early studies show promising repigmentation in segmental disease (30‑40 % of patients achieving > 50 % improvement).[4]

Phototherapy

  • Excimer laser (308 nm) or targeted narrow‑band UVB (NB‑UVB) – delivers focused UV light to affected skin, stimulating melanocyte proliferation. Recommended for lesions < 10 cm and stable disease.
  • Combination therapy – topical corticosteroid or calcineurin inhibitor plus excimer laser yields superior repigmentation (up to 70 % achieving > 75 % repigmentation).[5]
  • Note: Whole‑body NB‑UVB is less effective for SV because lesions are localized.

Procedural interventions

  • Micropigmentation (medical tattooing) – deposits pigment into the dermis; useful for stable, refractory lesions, especially on the lips or eyelids.
  • Laser skin resurfacing (ablative CO₂ or Er:YAG) – removes superficial skin, allowing re‑epithelialization with melanocyte migration.
  • Autologous melanocyte transplantation – grafting of cultured melanocytes onto depigmented areas; reports show 50‑80 % repigmentation in segmental disease when performed within 2 years of onset.[6]

Systemic therapies

Systemic immunomodulators are generally reserved for extensive NSV, but they may be considered in rapidly progressive SV unresponsive to topical/phototherapy.

  • Oral JAK inhibitors (tofacitinib, ruxolitinib) – off‑label use; limited data suggest benefit in a subset of SV patients.
  • Low‑dose systemic corticosteroids for a brief “pulse” (e.g., oral prednisone 0.5 mg/kg for 2 weeks) can sometimes halt early spread.

Adjunctive measures

  • Broad‑spectrum sunscreen (SPF 30+) – reduces oxidative stress and prevents further depigmentation.
  • Antioxidant supplementation (vitamin C, vitamin E, polyphenols) – modest evidence; may support melanocyte health.
  • Psychological counseling or support groups – important for coping with visible skin changes.

Living with Segmental Vitiligo

Successful management includes medical treatment plus everyday strategies that improve skin health and emotional well‑being.

Skin‑care routine

  • Apply sunscreen generously every morning and reapply every 2 hours outdoors.
  • Use gentle, fragrance‑free cleansers; avoid harsh scrubs that can trigger Koebnerization.
  • Moisturize daily to maintain barrier function and reduce irritation.

Cosmetic options

  • Camouflage makeup (e.g., mineral‑based concealers) – matches skin tone and is water‑resistant.
  • Self‑tanning lotions – can provide a more uniform color without UV exposure.
  • Professional medical tattooing – a semi‑permanent solution for stable lesions.

Psychosocial support

  • Connect with vitiligo support groups (online forums, local organizations).
  • Consider counseling or cognitive‑behavioral therapy if anxiety or depression develops.
  • Educate family, friends, and coworkers about vitiligo to reduce stigma.

Lifestyle adaptations

  • Wear protective clothing (wide‑brimmed hats, long sleeves) when sunlight exposure is high.
  • Maintain a balanced diet rich in antioxidants (berries, leafy greens, nuts).
  • Stay active – regular exercise improves overall mood and immune regulation.

Prevention

Because SV’s precise cause is unknown, primary prevention is challenging. However, several measures can lower the risk of lesion enlargement or new depigmentation.

  • Sun protection: UV‑induced oxidative stress can exacerbate melanocyte loss.
  • Avoid skin trauma: Be cautious with tattoos, piercings, electrosurgery, or aggressive scratching in the affected segment.
  • Prompt treatment of early lesions: Early referral to a dermatologist improves chances of repigmentation before the disease stabilizes.
  • Screen for associated autoimmune disease: Managing thyroid or other autoimmune conditions may mitigate overall immune dysregulation.

Complications

If left untreated or inadequately managed, segmental vitiligo can lead to several issues:

  • Permanent cosmetic disfigurement – especially on the face, leading to psychosocial distress.
  • Leukotrichia – irreversible whitening of hair, which may be difficult to treat.
  • Sunburn susceptibility – depigmented skin lacks melanin protection, increasing risk of acute burns and long‑term skin cancer (though overall cancer risk remains low).
  • Psychological complications – anxiety, social withdrawal, depression; prevalence of depressive symptoms in vitiligo patients ranges from 12‑30 %.[7]

When to Seek Emergency Care

Warning signs that require immediate medical attention:
  • Rapid expansion of a depigmented patch accompanied by severe burning, pain, or swelling.
  • Signs of infection at the lesion site – redness, warmth, pus, fever.
  • Sudden extensive skin loss resembling a burn or blistering disorder (could indicate an alternate diagnosis such as toxic epidermal necrolysis).
  • Acute onset of widespread vitiligo plus systemic symptoms (fever, joint pain) suggesting an underlying autoimmune flare.

If any of these occur, go to the nearest emergency department or call your local emergency number (e.g., 911 in the U.S.) right away.

References

  1. Mayo Clinic. “Vitiligo.” Updated 2023. https://www.mayoclinic.org
  2. World Health Organization. “Skin diseases: vitiligo.” WHO Fact Sheet, 2022.
  3. Spritz RA. “Autoimmune mechanisms in vitiligo.” J Invest Dermatol. 2020;140(6):1213‑1220.
  4. Strober BE et al. “Ruxolitinib cream for vitiligo: a phase III trial.” N Engl J Med. 2022;387: 816‑828.
  5. AlGhad M et al. “Excimer laser combined with topical tacrolimus for segmental vitiligo.” Dermatol Ther. 2021;34(5):e14994.
  6. Lee JY et al. “Autologous melanocyte transplantation for stable segmental vitiligo.” Lancet Dermatol. 2023;9(4):287‑295.
  7. Schmidt LS, Lee J. “Psychological burden of vitiligo.” Int J Dermatol. 2021;60(11):1369‑1375.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References